Target-oriented therapy: Emerging drugs for atopic dermatitis

References

• Ring J. Atopic Dermatitis. Berlin: Springer Verlag; 2016.
   Google Scholar
• Ring J, Przybilla B, Ruzicka T. Handbook of atopic eczema. 2nd ed. Berlin: Springer Verlag; 2006.
   Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2015;11.
   Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494.
   PubMed Web of Science ®Google Scholar
• Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One. 2012;7(7):e39803.
   PubMed Web of Science ®Google Scholar
• Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68(4):498–506.
   PubMed Web of Science ®Google Scholar
• Deckert S, Kopkow C, Schmitt J. Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy. 2014;69(1):37–45.
   PubMed Web of Science ®Google Scholar
• Ring J. Terminology of allergic phenomena. Chem Immunol Allergy. 2014;100:46–52.
   PubMedGoogle Scholar
• Brodská P, Panzner P, Pizinger K, et al. IgE-mediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type. Dermatitis. 2014;25(3):120–126.
   PubMed Web of Science ®Google Scholar
• Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925–931.
   PubMed Web of Science ®Google Scholar
• Martin PE, Eckert JK, Koplin JJ, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy. 2015;45(1):255–264.
   PubMed Web of Science ®Google Scholar
• De Benedictis FM, Franceschini F, Hill D, et al. The allergic sensitization in infants with atopic eczema from different countries. Allergy. 2009;64(2):295–303.
   PubMed Web of Science ®Google Scholar
• Eller E, Kjaer HF, Høst A, et al. Food allergy and food sensitization in early childhood: results from the DARC cohort. Allergy. 2009;64(7):1023–1029.
   PubMed Web of Science ®Google Scholar
• Eyerich K, Eyerich S, Biedermann T. The Multi-Modal Immune Pathogenesis of Atopic Eczema. Trends Immunol. 2015;18:788–801.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Boyman O, Kaegi C, Akdis M, et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy. 2015;70(7):727–754.
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060.
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176–1193.
   PubMed Web of Science ®Google Scholar
• Leitch CS, Chu R, Ray R, et al. Edinburgh Dermatology Virtual Journal C. Preventing atopic eczema from birth using emollients. J Allergy Clin Immunol. 2015;135(6):1663–1664.
   PubMed Web of Science ®Google Scholar
• Mason JM, Carr J, Buckley C, et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol. 2013;13:7.
   PubMedGoogle Scholar
• van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, et al. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev. 2014;3:25.
   PubMedGoogle Scholar
• Garritsen FM, Brouwer MW, Limpens J, et al. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170(3):501–513.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–619.
   PubMed Web of Science ®Google Scholar
• Granlund H, Erkko P, Sinisalo M, et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol. 1995;132(1):106–112.
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–359.
   PubMed Web of Science ®Google Scholar
• Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(6):1074–1084.
   PubMed Web of Science ®Google Scholar
• Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6.
   PubMed Web of Science ®Google Scholar
• Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3–16.
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446.
   PubMed Web of Science ®Google Scholar
• Hirota T, Takahashi A, Kubo M, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet. 2012;44(11):1222–1226.
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Baurecht H, Esparza-Gordillo J, et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nat Genet. 2013;45(7):808–812.
   PubMed Web of Science ®Google Scholar
• Ring J, Möhrenschlager M. Allergy to peanut oil–clinically relevant?. J Eur Acad Dermatol Venereol. 2007;21(4):452–455.
   PubMed Web of Science ®Google Scholar
• Lack G, Fox D, Northstone K, et al. Avon Longitudinal Study of P, Children Study T. Factors associated with the development of peanut allergy in childhood. N Engl J Med. 2003;348(11):977–985.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–54.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6):1244–52 e2.
   PubMed Web of Science ®Google Scholar
• Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974–982.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Kitoh A, Egawa G, et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol. 2014;134(8):2122–2130.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7–R12.
   PubMed Web of Science ®Google Scholar
• Liu YJ, Soumelis V, Watanabe N, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193–219.
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Roan F, Bell BD, et al. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129–155.
   PubMedGoogle Scholar
• Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–760.
   PubMed Web of Science ®Google Scholar
• Toyoda M, Nakamura M, Makino T, et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147(1):71–79.
   PubMed Web of Science ®Google Scholar
• Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122(2):421–423.
   PubMed Web of Science ®Google Scholar
• Simon D, Aeberhard C, Erdemoglu Y, et al. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy. 2014;69(1):125–131.
   PubMed Web of Science ®Google Scholar
• Mittermann I, Aichberger KJ, Bünder R, et al. Autoimmunity and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2004;4(5):367–371.
   PubMedGoogle Scholar
• Kobayashi T, Glatz M, Horiuchi K, et al. Dysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis. Immunity. 2015;42(4):756–766.
   PubMed Web of Science ®Google Scholar
• Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–9.
   PubMed Web of Science ®Google Scholar
• Skabytska Y, Wolbing F, Gunther C, et al. Cutaneous innate immune sensing of Toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity. 2014;41(5):762–775.
   PubMed Web of Science ®Google Scholar
• McCarron EP, Williams DP, Antoine DJ, et al. Exploring the translational disconnect between the murine and human inflammatory response: analysis of LPS dose-response relationship in murine versus human cell lines and implications for translation into murine models of sepsis. J Inflamm Res. 2015;8:201–209.
   PubMedGoogle Scholar
• Murrell DF, Gebauer K, Spelman L, et al. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study. J Drugs Dermatol. 2015;14(10):1108–1112.
   PubMed Web of Science ®Google Scholar
• Hebert AAEL, Lebwohl MG et al. Evaluation of pruritus and signs of atopic dermatitis with crisaborole topical ointment, 2% a novel nosteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor, in two phase 3 studies in children and adults with mild to moderate atopic dermatitis. 34th Fall Clinical Dermatology Conference, Las Vegas, NV; 2015; 2015.
   Google Scholar
• Volf EM, Au SC, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11(3):341–346.
   PubMed Web of Science ®Google Scholar
• Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 2012;148(8):890–897.
   PubMedGoogle Scholar
• Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44(8):1044–1052.
   PubMed Web of Science ®Google Scholar
• Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37–44.
   PubMed Web of Science ®Google Scholar
• Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2014;133(2):414–419.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al.. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al.. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, et al.. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2015;7.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300.
   PubMed Web of Science ®Google Scholar
• Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75(1):68–78.
   PubMed Web of Science ®Google Scholar
• Eyerich S, Eyerich K, Cavani A, et al. IL-17 and IL-22: siblings, not twins. Trends Immunol. 2010;31(9):354–361.
   PubMed Web of Science ®Google Scholar
• Fernández-Antón Martínez MC, AlfagemeRoldán F, Ciudad Blanco C, et al. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105(3):312–313.
   PubMedGoogle Scholar
• Samorano LP, Hanifin JM, Simpson EL, et al. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol. 2014;16.
   PubMed Web of Science ®Google Scholar
• Agusti-Mejias A, Messeguer F, García R, et al. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 2013;25(3):368–370.
   PubMed Web of Science ®Google Scholar
• Puya R, Alvarez-López M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51(1):115–116.
   PubMed Web of Science ®Google Scholar
• Andres C, Belloni B, Mempel M, et al. Omalizumab for patients with severe and therapy-refractory atopic eczema?. Curr Allergy Asthma Rep. 2008;8(3):179–180.
   PubMed Web of Science ®Google Scholar
• Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998.
   PubMed Web of Science ®Google Scholar
• Ramirez del PME, Contreras CE, Lopez TJ, et al. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol. 2011;21(5):416–417.
   PubMed Web of Science ®Google Scholar
• Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab. Acta Derm Venereol. 2015;10:72–76.
   Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Tauber M, Balica S, Hsu CY, et al. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. J Allergy Clin Immunol. 2015;7:189–197.
   Web of Science ®Google Scholar
• Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol. 2008;159(6):1357–1363.
   PubMed Web of Science ®Google Scholar
• Otsuka A, Doi H, Egawa G, et al. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol. 2014;133(1):139–46 e1–10.
   Web of Science ®Google Scholar
• Rossbach K, Schaper K, Kloth C, et al.. Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis. Allergy. 2015;6:189–197.
   Google Scholar
• Rothe M, Quarcoo D, Chashchina AA, et al. IL-13 but not IL-4 signaling via IL-4Ralpha protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis. Cancer Med. 2013;2(6):815–825.
   PubMed Web of Science ®Google Scholar